A Multicenter, Open-Label, Randomized Study Comparing Efficacy and Safety of S-1 as Single Agent Versus 5-FU Bolus for the Treatment of Patients With Metastatic Pancreatic Cancer Previously Treated With a Gemcitabine-Based Regimen.

Trial Profile

A Multicenter, Open-Label, Randomized Study Comparing Efficacy and Safety of S-1 as Single Agent Versus 5-FU Bolus for the Treatment of Patients With Metastatic Pancreatic Cancer Previously Treated With a Gemcitabine-Based Regimen.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 May 2016

At a glance

  • Drugs Fluorouracil; Gimeracil/oteracil/tegafur
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 05 May 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top